期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Efficacy and Safety of Tinefcon® Tablets in Subjects with Plaque Psoriasis: An Open Label, Non-Comparative, Multicenter, Phase IV Trial
1
作者 Somesh Sharma Kailash Bhatia +26 位作者 Meetesh Agarwal Sandesh Gupta Leelavathi Budamakuntla Sudhakar Grandhi Vinod Titarmare Sushil Pande Ranjan Rawal Aruna Samarth Rizwan Haq Vikrant Saoji D. V. S. Pratap L. M. Kansal D. G. Saple Shatrughan Sahay Parag Kalyani Puneet Goyal Sharmila Patil A. J. Kanwar Bhavesh Swarnakar Sujay Kulkarni Abhijeet Morde Hitesh Khandagale Yogesh Dound Nitin Jadhav Sanjeev Hegde Murlidhara Padigaru Ashish C. Suthar 《Journal of Cosmetics, Dermatological Sciences and Applications》 2016年第2期55-66,共12页
Importance: This post-marketing surveillance study was conducted to evaluate real-world information about the efficacy and safety of oral Tinefcon<sup>?</sup> tablets (Sphaeranthus indicus based) in plaque... Importance: This post-marketing surveillance study was conducted to evaluate real-world information about the efficacy and safety of oral Tinefcon<sup>?</sup> tablets (Sphaeranthus indicus based) in plaque psoriasis patients. Materials and Methods: Patients aged at least 18 years and older with clinical diagnosis of plaque psoriasis, were enrolled in this open label, non-comparative, multicenter trial. All eligible subjects received four 700 mg Tinefcon<sup>?</sup> tablets/day for 12 weeks. The primary outcome measure was percent change in Psoriasis Area Severity Index (PASI) score from baseline to week 12. The secondary outcome measures were Physician Global Assessment (PGA), Nail Psoriasis Severity Index (NAPSI), Psoriatic Arthritis Evaluation and Gene Expression Profiling and Immunohistochemistry. Results: After completion of Tinefcon<sup>?</sup> treatment at 12 weeks, more than half of subjects (52%) achieved PASI 50 response;PASI 75 response was attained in 68 (23%) subjects and PASI 90 response in 22 (7%) subjects. Five subjects with severe psoriasis achieved PASI 90 without receiving any concomitant medication. Reduction in severity as assessed by PGA was observed in more than half of patients with moderate disease. Histopathological evaluation revealed that epidermal thickness was considerably reduced in 66% of subjects. The expression of inflammatory marker S100A9 protein was(meaningfully reduced in 60% patients with non-significant reduction of Keratin 10 protein expression. Gene expression analysis showed increase down regulation of SERPINB4;PI3 and KRT16 genes after a 12-week treatment period in subjects with higher PASI scores. Conclusion: Oral Tinefcon<sup>?</sup> tablets showed good efficacy and had a favorable safety profile in plaque psoriasis patients. 展开更多
关键词 PSORIASIS Tinefcon® Tablet Sphaeranthus indicus
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部